Indicator 3.3.4 - Hepatitis B incidence per 100,000 population
Reported acute hepatitis B cases per 100,000 US population
Reported acute hepatitis B cases per 100,000 US population
Global Metadata
This table provides information on metadata for SDG indicators as defined by the United Nations Statistical Commission. Complete global metadata documentation on all indicators in Goal 3, unless otherwise noted, is provided by the UN Statistics Division.
| SDG Indicator Name | Hepatitis B incidence per 100,000 population |
|---|---|
| SDG Target Addressed | By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases. |
| Definition of SDG Indicator | The number of new hepatitis B infections per 100,000 population in a given year is estimated from the prevalence of total antibodies against hepatitis B core antigen (Total anti_HBc) and hepatitis B surface antigen (HBsAg) positive among children 5 years of age, adjusted for sampling design. |
| UN Designated Tier | 2 |
| UN Custodial Agency | WHO |
U.S. Metadata
This table provides metadata for the actual indicator available from U.S. statistics closest to the corresponding global SDG indicator. Please note that even when the global SDG indicator is fully available from U.S. statistics, this table should be consulted for information on national methodology and other US-specific metadata information
| Method of computation for global SDG indicator | Number of survey participants with Total anti_HBc and HBsAg positive test / Number in survey with Total anti_Hc/HBsAg result Method of measurement Total anti_HBc reflect cumulated incidence in the first five years of life while HBsAg reflect chronic infections that may evolve towards chronic liver diseases The sample of the serological survey must be drawn from the specific geographic region to be verified. For example if the purpose is to estimate national transmission of HBV (including mother_to_child transmission) then the sampling should be geographically representative of the population. Convenience sampling is not appropriate. The sample size should be adequate to show with 95% confidence HBsAg prevalence of less than 1% with a precision of ' 0.5%. The target age is 5_years_old. Sampling 4 ' 6 year olds may be appropriate. The serosurvey is cross sectional and therefore a point estimate time. The shorter time periods of data collection are therefore preferred. Data on HBV birth dose exposure and B3 completion are drawn from official records. Where these are not available testing for HBsAb may be considered for the serosurvey. This is less preferable as it is more costly, but can also be done in addition. Specimen collection and transportation should be appropriate to minimize bias though specimen degradation in rural and remote areas. Where possible, it is advantageous to collect blood specimens for ELISA laboratory testing because the accuracy (sensitivity and specificity) is higher than for rapid tests. However in some locations only rapid tests will be available hence test selection is resource dependent. This should be considered in designing overall study methodology. When an appropriate sampling strategy and size are used and quality testing assays and laboratory procedures are employed,the HBsAg prevalence in the serosurvey should be representative of the incidence of childhood HBV transmission in the specific geographic region (or country) in this age group. |
|---|---|
| Graph Title | Reported acute hepatitis B cases per 100,000 US population |
| Actual indicator available | The number of acute hepatitis B cases that are reported from U.S. states and territories to the National Centers for Disease Control and Prevention per 100,000 population in a given year by sex, age group, and race or ethnicity. |
| Description of actual indicator available | Annual rate of acute hepatitis B cases reported per 100,000 U.S. population by sex, age group, and race-ethnicity in, 2007 - 2015 |
| Method of computation | Number of cases reported, divided by U.S. population (in population segment of interest), multiplied by 100,000. |
| Comments and limitations | |
| Periodicity | Annual |
| Time Period | 2007-2015 |
| Unit of measure | cases per 100,000 population |
| Disaggregation #1 (Industry or social categories) | sex, age-group, and race-ethnicity |
| Disaggregation #2 (Geographical coverage) | National and by state (only national data provided) |
| Date of public data release from National source | November 2017 |
| Date of last Update of This Page | 2017-10-15 |
| Scheduled Update by National source | November 2018 |
| Scheduled Update by SDG Team | |
| Data Source1 (Agency STAFF NAME) | Benedict Truman |
| Data Source2 (Staff E-MAIL) | bit1@cdc.gov |
| Data Source3 (Agency/Survey/Dataset name) | Surveillance of Viral Hepatitis – United States, 2013, 2014 |
| Indicator web address (closest to data provided) | http://http://www.cdc.gov/hepatitis/statistics/2013surveillance/index.htm; www.cdc.gov/hepatitis/statistics/2014surveillance/index.htm |
| International and National References | http://www.cdc.gov/hepatitis/statistics/ |